<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="915bde4c-a9ec-4e3d-b0d2-7b10c93230dc"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZORYVE foam, 0.3%, safely and effectively. See full prescribing information for ZORYVE foam, 0.3%. <br/>
      <br/>ZORYVE<sup>®</sup> (roflumilast) topical foam, 0.3% <br/>Initial U.S. Approval: 2011</title>
   <effectiveTime value="20250527"/>
   <setId root="f9e0b4a9-a227-4947-b00c-41fb18d16589"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080642948" root="1.3.6.1.4.1.519.1"/>
            <name>Arcutis Biotherapeutics, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="c84d57b6-7a66-4288-b547-41c270ed835d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250527"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="80610-430" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZORYVE</name>
                        <formCode code="C42888" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AEROSOL, FOAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>roflumilast</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="3" unit="mg"/>
                              <denominator value="1" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0P6C6ZOP5U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>roflumilast</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0P6C6ZOP5U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>roflumilast</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="099WOY1SA3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ceteareth-10 phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETOSTEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4O6GCK4CTJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetearyl phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A1A1I8X02B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>diethylene glycol monoethyl ether</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="KEH0A3F75J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hexylene glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8CRQ2TH63M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>isopropyl palmitate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>methylparaben</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propylparaben</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B6E5W8RQJ4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>white petrolatum</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6LV4FOR43R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>butane</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BXR49TP611" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>isobutane</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T75W9911L6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>propane</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43180" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAN"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="80610-430-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231215"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217242" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231215"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>off white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="321505b7-c84e-4fcc-a91d-5db24db4d320"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table styleCode="Noautorules" width="100%">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage, Plaque Psoriasis (<linkHtml href="#S1.2">1.2</linkHtml>)</td>
                                 <td>5/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="6551d0e4-d0c3-4078-bda1-14705668e72d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZORYVE topical foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>seborrheic dermatitis in adult and pediatric patients 9 years of age and older. (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="ebba1f7c-3fbc-44a7-aef7-10c1bc8cc97f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Seborrheic Dermatitis</title>
                     <text>
                        <paragraph>ZORYVE<sup>®</sup> topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="67f76b59-67b4-487b-9c4c-5f26c0a92927"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Plaque Psoriasis</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="30f6ed86-c055-41dc-9c01-aaa83a92dca8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Shake can prior to each use. Apply a thin layer of ZORYVE foam, 0.3%, once daily to affected areas of body and/or scalp when they are not wet. Rub in completely.</paragraph>
                  <paragraph>Wash hands after application.</paragraph>
                  <paragraph>Avoid fire, flame, and smoking during and immediately following application <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>ZORYVE foam, 0.3%, is for topical use only and not for ophthalmic, oral, or intravaginal use.</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Apply once daily to affected areas. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>For topical use only. Not for ophthalmic, oral, or intravaginal use. (<linkHtml href="#S2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="2ceef2f7-0e08-4b08-bc7d-3e323d112529"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Topical foam, 0.3%: 3 mg of roflumilast per gram of white to off-white foam in 60-gram pressurized cans.</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Topical foam, 0.3%: 3 mg of roflumilast per gram in 60-gram pressurized cans. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4cc25fdf-4d99-414b-9412-54c70570b6e9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ZORYVE foam, 0.3%, is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C) <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Moderate to severe liver impairment (Child-Pugh B or C). (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="c334e28f-759f-46cc-9eb8-3aee686260ae"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Flammability</content>: The propellants in ZORYVE foam, 0.3%, are flammable. Avoid fire, flame, and smoking during and immediately following application. (<linkHtml href="#S5.1">5.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="48d29176-19b5-41fc-bad5-097c570cd8ef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Flammability</title>
                     <text>
                        <paragraph>The propellants in ZORYVE foam, 0.3%, are flammable. Avoid fire, flame, and smoking during and immediately following application.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="25dde210-1ddf-41fb-9baf-291dcee372c6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (reported in ≥ 1% of patients) are:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Seborrheic dermatitis</content>: nasopharyngitis, nausea, and headache. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Plaque psoriasis of the scalp and body</content>: headache, diarrhea, nausea, and nasopharyngitis. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Arcutis Biotherapeutics, Inc. at 1-844-692-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="7a714358-61d4-4576-a6fd-d5b29237485a"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="92400719-35af-4810-8a6d-80eed57cda1b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Seborrheic Dermatitis</content>
                              </paragraph>
                              <paragraph>In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 203 and STRATUM), 683 adult and pediatric subjects 9 years of age or older with seborrheic dermatitis were treated with ZORYVE foam, 0.3%, or vehicle foam once daily for 8 weeks <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Table 1 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE foam, 0.3%.</paragraph>
                              <table width="50%">
                                 <caption>Table 1: Adverse Reactions Reported in ≥1% of Adult and Pediatric Subjects 9 Years of Age and Older with Seborrheic Dermatitis Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 203 and Trial STRATUM</caption>
                                 <col width="35%" align="left" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction	</th>
                                       <th styleCode="Rrule">ZORYVE foam, 0.3%<br/>(N=458)<br/>n (%)</th>
                                       <th styleCode="Rrule">Vehicle foam<br/>(N=225)<br/>n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                       <td styleCode="Rrule">7 (1.5)</td>
                                       <td styleCode="Rrule">1 (0.4)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">	6 (1.3)</td>
                                       <td styleCode="Rrule">0 (0)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">5 (1.1)</td>
                                       <td styleCode="Rrule">0 (0)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The following additional adverse reactions were reported in fewer than 1% of subjects treated with ZORYVE foam, 0.3%: diarrhea and insomnia.</paragraph>
                              <paragraph>The adverse reaction profile in pediatric subjects was consistent with that observed in adults <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                              <paragraph>In 408 subjects who continued treatment with ZORYVE foam, 0.3%, for up to 24 to 52 weeks in an open-label, long-term trial, the adverse reaction profile was consistent with that observed in vehicle-controlled trials.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="97de4a00-b1b4-47c1-8513-c4bbdaf74733"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Plaque Psoriasis</content>
                              </paragraph>
                              <paragraph>In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 204 and ARRECTOR), 734 adult and pediatric subjects 12 years of age and older with plaque psoriasis of the scalp and body were treated with ZORYVE foam, 0.3%, or vehicle foam once daily for 8 weeks <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Table 2 presents adverse reactions that occurred in at least 1% of subjects treated with ZORYVE foam, 0.3%.</paragraph>
                              <table width="50%">
                                 <caption>Table 2: Adverse Reactions Reported in ≥1% of Adult and Pediatric Subjects 12 Years of Age and Older with Plaque Psoriasis of the Scalp and Body Treated with ZORYVE Foam, 0.3%, for 8 Weeks in Trial 204 and Trial ARRECTOR</caption>
                                 <col width="35%" align="left" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">ZORYVE foam, 0.3%<br/>(N=479)<br/>n (%)</th>
                                       <th styleCode="Rrule">Vehicle foam<br/>(N=255)<br/>n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">15 (3.1)</td>
                                       <td styleCode="Rrule">3 (1.2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">12 (2.5)</td>
                                       <td styleCode="Rrule">4 (1.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">8 (1.7)</td>
                                       <td styleCode="Rrule">0 (0)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                       <td styleCode="Rrule">6 (1.3)</td>
                                       <td styleCode="Rrule">2 (0.8)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The following additional adverse reaction was reported in fewer than 1% of subjects treated with ZORYVE foam, 0.3%: insomnia.</paragraph>
                              <paragraph>The adverse reaction profile in pediatric subjects was consistent with that observed in adults <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="287fffd6-4b5a-4a01-bf2f-30eb9377e3c4"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250527"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Co-administration of roflumilast with systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously may increase roflumilast systemic exposure and may result in increased adverse reactions. If these products are co-administered with ZORYVE foam, 0.3%, weigh the potential for increased adverse reactions against benefit. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Co-administration of roflumilast with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased adverse reactions. If these products are co-administered with ZORYVE foam, 0.3%, weigh the potential for increased adverse reactions against benefit. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="4b677251-8976-40b1-8c04-27e69b890485"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effects of Other Drugs on ZORYVE Foam, 0.3%</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="31c9a2ab-edbf-4fda-a27f-ea8aa9e043d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drugs that Inhibit Cytochrome P450 (CYP) Enzymes</content>
                              </paragraph>
                              <paragraph>No formal drug-drug interaction studies were conducted with ZORYVE foam, 0.3%; however, the co-administration of oral roflumilast with systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously may increase roflumilast systemic exposure and may result in increased adverse reactions. If these products are co-administered with ZORYVE foam, 0.3%, weigh the potential for increased adverse reactions against benefit <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7182fb7e-465f-4a77-b5a9-f3b296930ad2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Oral Contraceptives Containing Gestodene and Ethinyl Estradiol</content>
                              </paragraph>
                              <paragraph>The co-administration of roflumilast with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased adverse reactions. If these products are co-administered with ZORYVE foam, 0.3%, weigh the potential for increased adverse reactions against benefit <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="73f3cfe2-d25b-442b-b38b-e0ac1abe428e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250527"/>
               <component>
                  <section ID="S8.1">
                     <id root="547a184a-da4d-4b38-978f-ce15e4c9b3f9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="2704015f-0002-4419-aafe-f959d7d6730d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are insufficient data available on the use of ZORYVE foam, 0.3%, in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, roflumilast administered orally to pregnant rats and rabbits during the period of organogenesis produced no fetal structural abnormalities at doses up to 21 and 18 times the maximum recommended human dose (MRHD), respectively. Roflumilast induced post-implantation loss in rats at oral doses greater than or equal to 7 times the MRHD. Roflumilast induced stillbirth and decreased pup viability in mice at oral doses 11 and 34 times the MRHD, respectively. Roflumilast has been shown to adversely affect pup post-natal development when dams were treated with an oral dose 34 times the MRHD during pregnancy and lactation periods in mice <content styleCode="italics">(see <linkHtml href="#Data1">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8f02647d-e9ce-4a8c-b24c-3c149b3481f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="bf76a563-b15a-4db5-9b90-98c0f0083f51"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor and delivery</content>
                                    </paragraph>
                                    <paragraph>Avoid using ZORYVE foam, 0.3%, during labor and delivery. There are no human studies that have investigated effects of ZORYVE foam, 0.3%, on preterm labor or labor at term; however, animal studies showed that oral roflumilast disrupted the labor and delivery process in mice.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data1">
                           <id root="3d176b46-3bad-4748-834c-983a84b037f7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="b58e5796-33e0-491c-9370-17f2de54e8ce"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study, pregnant rats were dosed orally during the period of organogenesis with up to 1.8 mg/kg/day roflumilast (21 times the MRHD on a mg/m<sup>2</sup> basis). No evidence of structural abnormalities or effects on survival rates were observed. Roflumilast did not affect embryo-fetal development at a maternal oral dose of 0.2 mg/kg/day (2 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                                    <paragraph>In a fertility and embryo-fetal development study, male rats were dosed orally with up to 1.8 mg/kg/day roflumilast for 10 weeks and females for 2 weeks prior to pairing and throughout the organogenesis period. Roflumilast induced pre- and post-implantation loss at maternal oral doses greater than or equal to 0.6 mg/kg/day (7 times the MRHD on a mg/m<sup>2</sup> basis). Roflumilast did not cause fetal structural abnormalities at maternal oral doses up to 1.8 mg/kg/day (20 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                                    <paragraph>In an embryo-fetal development study in rabbits, pregnant does were dosed orally with 0.8 mg/kg/day roflumilast during the period of organogenesis. Roflumilast did not cause fetal structural abnormalities at the maternal oral doses of 0.8 mg/kg/day (18 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                                    <paragraph>In pre- and post-natal developmental studies in mice, dams were dosed orally with up to 12 mg/kg/day roflumilast during the period of organogenesis and lactation. Roflumilast induced stillbirth and decreased pup viability at maternal oral doses greater than 2 mg/kg/day and 6 mg/kg/day, respectively (11 and 34 times the MRHD on a mg/m<sup>2</sup> basis, respectively). Roflumilast induced delivery retardation in pregnant mice at maternal oral doses greater than 2 mg/kg/day (11 times the MRHD on a mg/m<sup>2</sup> basis). Roflumilast decreased pup rearing frequencies at a maternal oral dose of 6 mg/kg/day during pregnancy and lactation (34 times the MRHD on a mg/m<sup>2</sup> basis). Roflumilast also decreased survival and forelimb grip reflex and delayed pinna detachment in mouse pups at a maternal oral dose of 12 mg/kg/day (68 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="99386659-e22b-40ff-b068-c9ecef5da04d"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="1c4008ba-c690-4842-b8cb-bc4dd1925f87"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of roflumilast or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                              <paragraph>Roflumilast and/or its metabolites are excreted into the milk of lactating rats <content styleCode="italics">(see <linkHtml href="#Data2">Data</linkHtml>)</content>. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZORYVE foam, 0.3%, and any potential adverse effects on the breastfed infant from ZORYVE foam, 0.3%, or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="900d9883-8387-461d-a7c0-ded1d86814a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>To minimize potential exposure to the breastfed infant via breast milk, use ZORYVE foam, 0.3%, on the smallest area of skin and for the shortest duration possible while breastfeeding. To avoid direct infant exposure, advise breastfeeding women not to apply ZORYVE foam, 0.3%, directly to the nipple or areola. If applied to the patient's chest, avoid exposure via direct contact with the infant's skin.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="20d2613e-9c5b-45dc-b73e-bbd7c4b92370"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="77f88ce2-7988-4aed-9e91-b5712d3baac3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal data</content>
                                    </paragraph>
                                    <paragraph>Roflumilast and/or its metabolite concentrations measured 8 hours after an oral dose of 1 mg/kg given to lactating rats were 0.32 and 0.02 mcg/g in the milk and pup liver, respectively. The concentration of roflumilast in animal milk does not necessarily predict the concentration of drug in human milk.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="b0cafc64-a8bd-441d-8167-536fba116039"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Fertility</title>
                     <text>
                        <paragraph>In a human spermatogenesis study, oral roflumilast 500 mcg had no effects on semen parameters or reproductive hormones during the 3-month treatment period and the following 3-month off-treatment period.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="941b1c0a-ec2f-4b8b-983b-b302ebd257f6"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="26810bbe-61a2-4cf9-a5ff-6fd24a42c718"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Seborrheic Dermatitis</content>
                              </paragraph>
                              <paragraph>The safety and effectiveness of ZORYVE topical foam, 0.3%, for the treatment of seborrheic dermatitis have been established in pediatric patients 9 years of age and older. Use of ZORYVE foam, 0.3%, in this age group is supported by data from two 8-week, vehicle-controlled trials which included 32 subjects 9 to 17 years of age, of whom 17 received ZORYVE foam, 0.3%, and from open-label trials of up to 52 weeks which included 23 pediatric subjects treated with ZORYVE foam, 0.3% <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                              <paragraph>The safety and effectiveness of ZORYVE foam, 0.3%, in pediatric patients below the age of 9 years have not been established.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="04274344-8921-4860-b2c0-84613dbc283f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Plaque Psoriasis</content>
                              </paragraph>
                              <paragraph>The safety and effectiveness of ZORYVE topical foam, 0.3%, for the treatment of plaque psoriasis of the scalp and body have been established in pediatric patients 12 years of age and older. Use of ZORYVE foam, 0.3%, in this age group is supported by data from two 8-week, vehicle-controlled trials which included 12 subjects 12 to 17 years of age, of whom 8 received ZORYVE foam, 0.3%. Use of ZORYVE foam, 0.3%, in pediatric patients 12 years of age and older is also supported by data from an open-label trial of 8 weeks duration which included 7 subjects 12 to 17 years of age treated with ZORYVE foam, 0.3%.</paragraph>
                              <paragraph>The safety and effectiveness of ZORYVE foam, 0.3%, in pediatric patients below the age of 12 years with plaque psoriasis have not been established.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="b98481e7-c562-444f-8a46-790df0ead164"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="c0275180-081f-4edf-8363-7831ed77d158"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Seborrheic Dermatitis</content>
                              </paragraph>
                              <paragraph>Of the 683 subjects with seborrheic dermatitis exposed to ZORYVE foam, 0.3%, or vehicle for up to 8 weeks in the controlled clinical trials, 98 (14%) were 65 years of age or older, and 33 (5%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9c527966-e6d0-4746-baf6-ae193e5784de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Plaque Psoriasis</content>
                              </paragraph>
                              <paragraph>Of the 734 subjects with plaque psoriasis of the scalp and body exposed to ZORYVE foam, 0.3%, or vehicle for up to 8 weeks in the controlled clinical trials, 82 (11%) were 65 years of age or older, and 21 (3%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="e84cec70-d9a3-4416-bb5e-acdd6a7bd18f"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Oral roflumilast 250 mcg once daily for 14 days was studied in subjects with hepatic impairment. The systemic exposure of roflumilast and roflumilast N-oxide were increased in subjects with moderate (Child-Pugh B) hepatic impairment. ZORYVE foam, 0.3%, is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). No dosage adjustment is needed in patients with mild (Child-Pugh A) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="7c80f535-90e9-4b3a-bdd7-c98d8f0990e6"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ZORYVE (roflumilast) topical foam, 0.3%, is a white to off-white foam for topical use. The active ingredient, roflumilast, is a phosphodiesterase 4 (PDE4) inhibitor.</paragraph>
                  <paragraph>The chemical name of roflumilast is 3-cyclopropylmethoxy-<content styleCode="italics">N</content>-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide with a molecular formula of C<sub>17</sub>H<sub>14</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> and the molecular weight of 403.21.</paragraph>
                  <paragraph>The structural formula of roflumilast is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Roflumilast is practically insoluble in water and hexane, sparingly soluble in ethanol, and freely soluble in acetone.</paragraph>
                  <paragraph>Each gram of ZORYVE topical foam, 0.3%, contains 3 mg of roflumilast in a foam base containing ceteareth-10 phosphate, cetearyl phosphate, cetostearyl alcohol, diethylene glycol monoethyl ether, hexylene glycol, isopropyl palmitate, methylparaben, propylparaben, purified water, sodium hydroxide, and white petrolatum. Hydrochloric acid may have been added to adjust pH. ZORYVE topical foam, 0.3%, is dispensed from an aluminum can pressurized with propellant (butane, isobutane, and propane).</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="a74f1500-f924-46bd-88e3-f7d63b0a93a5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250527"/>
               <component>
                  <section ID="S12.1">
                     <id root="c9d82337-25be-40b8-bf5c-e2468e5b7bd3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of PDE4. Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic 3′,5′-adenosine monophosphate (cyclic AMP) metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP. The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="f56b39ef-30b9-4672-8fe3-0a4132249cac"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Pharmacodynamics of ZORYVE foam, 0.3%, in the treatment of seborrheic dermatitis and plaque psoriasis is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="742ae915-7000-4a62-b76e-351ada26acc6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250527"/>
                     <component>
                        <section>
                           <id root="6fa2ab3c-ca4b-429c-8b19-250ab76d9f7d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="0db064ae-997c-432d-9db7-8cc2f7ed180e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Seborrheic Dermatitis</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of ZORYVE foam, 0.3%, was investigated in 10 adult and 10 pediatric (11 to 16 years of age) subjects with seborrheic dermatitis. In this study, a mean dose of approximately 4.1 g of ZORYVE foam, 0.3%, was applied once daily for 15 days to a mean ± SD body surface area (BSA) involvement of 6.5 ± 1.08% and 5.5 ± 1.27% in adult and pediatric subjects, respectively. Plasma concentrations of roflumilast were quantifiable in all but two subjects at Day 15. Plasma concentrations of roflumilast N-oxide were quantifiable in all subjects at Day 15. Following application of ZORYVE foam, 0.3%, the plasma concentration versus time profile was relatively flat, with mean peak-to-trough ratios of 1.68 and 1.62 for roflumilast and roflumilast N-oxide, respectively.</paragraph>
                                    <paragraph>In adults, the mean ± SD maximum concentration (C<sub>max</sub>) was 2.2 ± 1.6 and 13.8 ± 9.0 ng/mL for roflumilast and the N-oxide metabolite, respectively. The mean ± SD systemic exposure (AUC<sub>0-24</sub>) was 36.6 ± 23.7 and 261 ± 190 h∙ng/mL for roflumilast and the N-oxide metabolite, respectively. In pediatric subjects, the extrapolated mean ± SD AUC<sub>0-24</sub> (based on pre-dose concentration) was 25.1 ± 30.2 and 253 ± 404 h∙ng/mL for roflumilast and the N-oxide metabolite, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="69049ca0-839f-4688-b3c4-97aeafb09403"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Plaque Psoriasis</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of ZORYVE foam, 0.3%, was investigated in 19 adults and 7 pediatric subjects 12 to 16 years of age with plaque psoriasis of the scalp and body. The entire scalp (BSA of approximately 4.5%) was treated in addition to the mean ± SD BSA involvement on the body of 25.0 ± 7.88% and 10.4 ± 0.54% in adults and pediatric subjects, respectively. In this study, the mean daily dose administered in adults was 10.3 g and in pediatric subjects from 12 to 16 years of age was 5.3 g of ZORYVE foam, 0.3%, once daily for 15 days. Following application of ZORYVE foam, 0.3%, the plasma concentration versus time profile was flat, with mean peak-to-trough ratios of approximately 1.2 for both roflumilast and roflumilast N-oxide.</paragraph>
                                    <paragraph>In adults, the mean ± SD C<sub>max</sub> was 4.48 ± 2.28 and 29.9 ± 17.5 ng/mL for roflumilast and the N-oxide metabolite, respectively, on Day 15. The mean ± SD AUC<sub>0-24</sub> was 90 ± 58.7 and 567 ± 436 h∙ng/mL for roflumilast and the N-oxide metabolite, respectively, on Day 15. In pediatric subjects, the extrapolated mean ± SD AUC<sub>0-24</sub> (based on pre-dose concentration) was 35.5 ± 41.4 and 270 ± 293 h∙ng/mL for roflumilast and the N-oxide metabolite, respectively, on Day 15.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7eae7c8a-a80e-4ba3-bb15-45ff33cd988c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Plasma protein binding of roflumilast and its N-oxide metabolite is approximately 99% and 97%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="741fc089-f750-443c-b62c-9d559ad3d015"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The plasma clearance after short-term intravenous infusion of roflumilast is on average about 9.6 L/h. Following topical administration, the mean half-lives of both roflumilast and the N-oxide metabolite were in the range of 3.6 to 5 days.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="45bf0d94-7211-4e8f-b34d-2ef3d8a57f4b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. The N-oxide metabolite is the only major metabolite observed in the plasma of humans. Following oral administration, roflumilast and roflumilast N-oxide account for the majority (87.5%) of total dose administered in plasma. Roflumilast was not detectable in urine, while roflumilast N-oxide was only a trace metabolite (less than 1%). Other conjugated metabolites such as roflumilast N-oxide glucuronide and 4-amino-3,5-dichloropyridine N-oxide were detected in urine.</paragraph>
                                    <paragraph>While roflumilast is 3 times more potent than roflumilast N-oxide at inhibition of the PDE4 enzyme <content styleCode="italics">in vitro</content>, the plasma AUC of roflumilast N-oxide on average is approximately 7-fold greater than the plasma AUC of roflumilast following topical administration. A similar ratio was observed following intravenous administration, whereas following oral administration the N-oxide metabolite circulated on average about 10-fold higher than the parent drug.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2974406e-6d9d-4420-957a-e7c4732de8cc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Following topical administration, no clinically significant differences in the pharmacokinetics of roflumilast and roflumilast N-oxide were observed based on age, sex, race, or ethnicity.</paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="3ed19fc9-1daf-45ed-8d00-ea476a39dae2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>No studies were conducted with topical roflumilast in subjects with hepatic impairment; however, oral roflumilast 250 mcg once daily for 14 days was studied in subjects with mild to moderate hepatic impairment classified as Child-Pugh A and B (8 subjects in each group). The AUC of roflumilast and roflumilast N-oxide were increased by 51% and 24%, respectively, in Child-Pugh A subjects and by 92% and 41%, respectively, in Child-Pugh B subjects, as compared to age-, weight-, and gender-matched healthy subjects. The C<sub>max</sub> of roflumilast and roflumilast N-oxide were increased by 3% and 26%, respectively, in Child-Pugh A subjects and by 26% and 40%, respectively, in Child-Pugh B subjects, as compared to healthy subjects <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="63725fbb-72a9-4bc4-9815-2e50171db859"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>No studies were conducted with topical roflumilast in subjects with renal impairment. Following oral administration in 12 subjects with severe renal impairment, no clinically significant differences in the pharmacokinetics of roflumilast and roflumilast N-oxide were observed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="17271d3d-67cc-40f1-bc19-ff3fbef89024"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250527"/>
                           <component>
                              <section>
                                 <id root="af4fef66-a1b8-4406-89db-8739c5dcf8a2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical Studies</content>
                                    </paragraph>
                                    <paragraph>No formal drug-drug interaction studies were conducted with roflumilast topical foam, 0.3%.</paragraph>
                                    <paragraph>Since a major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2, drug interaction studies were performed with oral roflumilast and systemic inhibitors of CYP3A4 and CYP1A2 <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                                 <component>
                                    <section>
                                       <id root="563a34a4-0637-44bb-af94-170a5a736dc2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Erythromycin</content>: In an open-label crossover study in 16 healthy volunteers, the co-administration of CYP3A4 inhibitor erythromycin (500 mg 3 times daily for 13 days) with a single oral dose of 500 mcg roflumilast resulted in 40% and 70% increase in C<sub>max</sub> and AUC for roflumilast, respectively, and a 34% decrease and a 4% increase in C<sub>max</sub> and AUC for roflumilast N-oxide, respectively.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="9a2dae64-ab7d-4c76-9097-52ba64487711"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Ketoconazole</content>: In an open-label crossover study in 16 healthy volunteers, the co-administration of a strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 13 days) with a single oral dose of 500 mcg roflumilast resulted in 23% and 99% increase in C<sub>max</sub> and AUC for roflumilast, respectively, and a 38% reduction and 3% increase in C<sub>max</sub> and AUC for roflumilast N-oxide, respectively.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="d0131e0d-37ef-4fbe-82fc-73a51a570e47"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Fluvoxamine</content>: In an open-label crossover study in 16 healthy volunteers, the co-administration of dual CYP 3A4/1A2 inhibitor fluvoxamine (50 mg daily for 14 days) with a single oral dose of 500 mcg roflumilast showed a 12% and 156% increase in roflumilast C<sub>max</sub> and AUC along with a 210% decrease and 52% increase in roflumilast N-oxide C<sub>max</sub> and AUC, respectively.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="3a08ed35-6783-4840-919e-0050a32872ac"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Enoxacin</content>: In an open-label crossover study in 16 healthy volunteers, the co-administration of dual CYP 3A4/1A2 inhibitor enoxacin (400 mg twice daily for 12 days) with a single oral dose of 500 mcg roflumilast resulted in an increased C<sub>max</sub> and AUC of roflumilast by 20% and 56%, respectively. Roflumilast N-oxide C<sub>max</sub> was decreased by 14% while roflumilast N-oxide AUC was increased by 23%.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="c4dd9212-72b3-4db6-be4e-e950f0a2a77e"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Cimetidine</content>: In an open-label crossover study in 16 healthy volunteers, the co-administration of a dual CYP 3A4/1A2 inhibitor cimetidine (400 mg twice daily for 7 days) with a single oral dose of 500 mcg roflumilast resulted in a 46% and 85% increase in roflumilast C<sub>max</sub> and AUC; and a 4% decrease in C<sub>max</sub> and 27% increase in AUC for roflumilast N-oxide, respectively.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="0f545c76-cb2e-427d-9b78-88b6c1e11378"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Oral Contraceptives Containing Gestodene and Ethinyl Estradiol</content>: In an open-label crossover study in 20 healthy adult volunteers, co-administration of a single oral dose of roflumilast with repeated doses of a fixed combination oral contraceptive containing 0.075 mg gestodene and 0.03 mg ethinyl estradiol to steady state caused a 38% increase and 12% decrease in C<sub>max</sub> of roflumilast and roflumilast N-oxide, respectively. Roflumilast and roflumilast N-oxide AUCs were increased by 51% and 14%, respectively.</paragraph>
                                       </text>
                                       <effectiveTime value="20250527"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="fb821bc8-943f-4806-8be5-bb06cfadfb11"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>Cytochrome P450 (CYP) Enzymes: <content styleCode="italics">In vitro</content> studies suggest that the biotransformation of roflumilast to its N-oxide metabolite is mediated by CYP1A2 and 3A4. Based on further <content styleCode="italics">in vitro</content> results in human liver microsomes, roflumilast and roflumilast N-oxide therapeutic plasma concentrations do not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, or 4A9/11; therefore, there is a low probability of relevant interactions with substances metabolized by these P450 enzymes. In addition, <content styleCode="italics">in vitro</content> studies demonstrated no induction of the CYP1A2, 2A6, 2C9, 2C19, or 3A4/5 and only a weak induction of CYP2B6 by roflumilast.</paragraph>
                                 </text>
                                 <effectiveTime value="20250527"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="8d25d849-76bb-4bba-a294-94be1ab75f0a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250527"/>
               <component>
                  <section ID="S13.1">
                     <id root="93f75d32-2574-4673-99f2-3a06f6c03c0f"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies were conducted in hamsters and mice with roflumilast to evaluate its carcinogenic potential. In 2-year oral gavage carcinogenicity studies, roflumilast treatment resulted in dose-related, statistically significant increases in the incidence of undifferentiated carcinomas of nasal epithelium in hamsters at doses greater than or equal to 8 mg/kg/day (11 times the MRHD on an AUC basis). The tumorigenicity of roflumilast appears to be attributed to a reactive metabolite of 4-amino-3,5-dichloropyridine N-oxide (ADCP N-oxide). No evidence of tumorigenicity was observed in mice at roflumilast oral doses up to 12 and 18 mg/kg/day in females and males, respectively (10 and 15 times the MRHD, respectively, on an AUC basis).</paragraph>
                        <paragraph>In a 2-year dermal mouse carcinogenicity study, no evidence of carcinogenicity was observed at topical doses of roflumilast cream up to 1% applied at 2 mL/kg/day (4 times the MRHD on an AUC basis).</paragraph>
                        <paragraph>Roflumilast tested positive in an <content styleCode="italics">in vivo</content> mouse micronucleus test, but negative in the following assays: the Ames test, an <content styleCode="italics">in vitro</content> chromosome aberration assay in human lymphocytes, an <content styleCode="italics">in vitro</content> HPRT assay with V79 cells, an <content styleCode="italics">in vitro</content> micronucleus test with V79 cells, a DNA adduct formation assay in rat nasal mucosa, liver, and testes, and an <content styleCode="italics">in vivo</content> mouse bone marrow chromosome aberration assay. Roflumilast N-oxide was negative in the Ames test and an <content styleCode="italics">in vitro</content> micronucleus test with V79 cells.</paragraph>
                        <paragraph>In a fertility study, oral roflumilast decreased fertility rates in male rats at 1.8 mg/kg/day (20 times the MRHD on a mg/m<sup>2</sup> basis). The male rats also showed increases in the incidence of tubular atrophy, degeneration in the testis, and spermiogenic granuloma in the epididymides. No effect on rat fertility rate or male reproductive organ morphology was observed at 0.6 mg/kg/day (7 times the MRHD on a mg/m<sup>2</sup> basis). In a female fertility study, no effect on fertility was observed up to the highest roflumilast dose of 1.5 mg/kg/day in rats (17 times the MRHD on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="4afc986a-fc8b-4eb1-9cba-a18ac0531b8f"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250527"/>
               <component>
                  <section ID="S14.1">
                     <id root="1a705731-6924-4975-b088-045e71fe500d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Seborrheic Dermatitis</title>
                     <text>
                        <paragraph>Two randomized, double-blind, vehicle-controlled trials (STRATUM [NCT04973228] and Trial 203 [NCT04091646]) enrolled a total of 683 adult and pediatric subjects with seborrheic dermatitis involving the scalp, face, and/or body with an Investigator Global Assessment (IGA) of moderate or severe (IGA of 3 or 4 on a 5-point scale from 0 to 4). In each trial, subjects were randomized 2:1 to receive ZORYVE foam, 0.3%, or vehicle foam applied once daily for 8 weeks. The combined trial population was 50% male, 79% White, 11% Black, 5% Asian, and 5% other races; for ethnicity, 79% identified as non-Hispanic/Latino and 21% identified as Hispanic/Latino. In Trial STRATUM, the trial population ranged in age from 9 to 87 years, including 7% of subjects who were 9 to 17 years of age and 12% of subjects who were 65 years of age or older. At baseline, 94% of subjects had an IGA score of 3 (moderate), and 6% had an IGA score of 4 (severe). At baseline, 67% of subjects had a Worst Itch-Numeric Rating Scale (WI-NRS) score of 4 or higher on a scale of 0 to 10. In Trial 203, the trial population ranged in age from 18 to 85 years, including 18% who were 65 years of age or older. At baseline, 93% of subjects had an IGA score of 3 (moderate), and 7% had an IGA score of 4 (severe). At baseline, 81% of subjects had a Worst Itch-Numeric Rating Scale (WI-NRS) score of 4 or higher on a scale of 0 to 10.</paragraph>
                        <paragraph>The primary endpoint was the proportion of subjects who achieved IGA treatment success at Week 8 (Table 3). Success was defined as a score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade improvement from baseline.</paragraph>
                        <table width="80%">
                           <caption>Table 3: IGA Treatment Success at Week 8 in Adult and Pediatric Subjects 9 Years of Age and Older with Moderate to Severe Seborrheic Dermatitis in Trial STRATUM and Trial 203</caption>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" colspan="2">STRATUM</th>
                                 <th styleCode="Rrule" colspan="2">Trial 203</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">ZORYVE foam, 0.3%</th>
                                 <th styleCode="Rrule">Vehicle foam</th>
                                 <th styleCode="Rrule">ZORYVE foam, 0.3%</th>
                                 <th styleCode="Rrule">Vehicle foam</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">Number of subjects randomized</th>
                                 <th styleCode="Rrule">N=304</th>
                                 <th styleCode="Rrule">N=153</th>
                                 <th styleCode="Rrule">N=154</th>
                                 <th styleCode="Rrule">N=72</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">Abbreviations: CI = Confidence Interval</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">IGA success<footnote>IGA treatment success was defined as an IGA score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade IGA score improvement from baseline at Week 8 (Multiple Imputation).</footnote>
                                 </td>
                                 <td styleCode="Rrule">79.5%</td>
                                 <td styleCode="Rrule">58.0%</td>
                                 <td styleCode="Rrule">73.1%</td>
                                 <td styleCode="Rrule">40.8%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Difference from Vehicle (95% CI)<footnote>Treatment difference and 95% CI are based on the CMH method stratified by pooled site and baseline IGA strata.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">20.6% (11.2%, 30.0%)</td>
                                 <td styleCode="Rrule" colspan="2">33.8% (20.3%, 47.4%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In Trial STRATUM, among subjects with a baseline WI-NRS score of at least 4 (67% of subjects), there was a higher percentage of subjects who achieved a reduction of at least 4 points from baseline at Week 8 in the group who received ZORYVE foam, 0.3%, compared to the group who received vehicle foam (62.8% vs. 40.6% for a treatment difference of 25.7% and 95% CI of (13.4, 38.1)).</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="a08202d3-9948-4c70-943b-806f145d330d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Plaque Psoriasis</title>
                     <text>
                        <paragraph>Two randomized, double-blind, vehicle-controlled trials (ARRECTOR [NCT05028582] and Trial 204 [NCT04128007]) enrolled a total of 736 adult and pediatric subjects 12 years of age and older with mild to severe plaque psoriasis of the scalp and body. In each trial, subjects were randomized 2:1 to receive ZORYVE foam, 0.3%, or vehicle foam applied once daily for 8 weeks. The combined trial population was 55% female, 85% White, 5% Black, 6% Asian, and 4% other races; for ethnicity, 79% identified as non-Hispanic/Latino and 19% identified as Hispanic/Latino. The median age was 47 years (range 12 to 87 years).</paragraph>
                        <paragraph>In Trial ARRECTOR, the trial population ranged in age from 12 to 87 years, including 2% of subjects who were 12 to 17 years of age and 13% of subjects who were 65 years of age or older. At baseline, 86% of subjects had a Scalp Investigator Global Assessment (S-IGA) score of 3 (moderate) on a 5-point scale of 0 to 4, and 14% had an S-IGA score of 4 (severe); 28% of subjects had a Body Investigator Global Assessment (B-IGA) score of 2 (mild), 67% of subjects had a B-IGA score of 3 (moderate), and 5% had a B-IGA score of 4 (severe). At baseline, 76% of subjects had a Scalp Itch-Numeric Rating Scale (SI-NRS) score of 4 or higher on a scale of 0 to 10 and 73% had a Worst Itch-Numeric Rating Scale (WI-NRS) score of 4 or higher.</paragraph>
                        <paragraph>In Trial 204, the trial population ranged in age from 12 to 87 years, including 1% of subjects who were 12 to 17 years of age, and 9% who were 65 years of age or older. At baseline, 11% of subjects had an S-IGA score of 2 (mild), 76% of subjects had an S-IGA score of 3 (moderate), and 13% had an S-IGA score of 4 (severe); 36% of subjects had a B-IGA score of 2 (mild), 59% of subjects had a B-IGA score of 3 (moderate), and 5% had a B-IGA score of 4 (severe). At baseline, 89% of subjects had an SI-NRS score of 4 or higher on a scale of 0 to 10.</paragraph>
                        <paragraph>In both trials, S-IGA treatment success, a primary endpoint in ARRECTOR and Trial 204, and B-IGA treatment success, a primary endpoint in ARRECTOR, were defined as a score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade improvement from baseline.</paragraph>
                        <table width="80%">
                           <caption>Table 4: S-IGA and B-IGA Treatment Success at Week 8 in Adult and Pediatric Subjects 12 Years of Age and Older with Plaque Psoriasis of the Scalp and Body in Trial ARRECTOR and Trial 204</caption>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" colspan="2">Trial ARRECTOR</th>
                                 <th styleCode="Rrule" colspan="2">Trial 204</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">ZORYVE foam, 0.3%</th>
                                 <th styleCode="Rrule">Vehicle foam</th>
                                 <th styleCode="Rrule">ZORYVE foam, 0.3%</th>
                                 <th styleCode="Rrule">Vehicle foam</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">Number of subjects randomized</th>
                                 <th styleCode="Rrule">N=281</th>
                                 <th styleCode="Rrule">N=151</th>
                                 <th styleCode="Rrule">N=200</th>
                                 <th styleCode="Rrule">N=104</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">Abbreviations: CI = Confidence Interval</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">S-IGA success<footnote ID="t4f1">S-IGA treatment success and B-IGA treatment success were defined as a score of "Clear" (0) or "Almost Clear" (1), plus a 2-grade score improvement from baseline at Week 8 (Multiple Imputation).</footnote>
                                 </td>
                                 <td styleCode="Rrule">66.4%</td>
                                 <td styleCode="Rrule">27.8%</td>
                                 <td styleCode="Rrule">56.7%</td>
                                 <td styleCode="Rrule">11.0%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from Vehicle (95% CI)<footnote ID="t4f2">Treatment difference and 95% CI are based on the CMH method stratified by pooled site and baseline IGA strata.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">37.1% (27.1%, 47.1%)</td>
                                 <td styleCode="Rrule" colspan="2">47.7% (37.9%, 57.5%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">B-IGA success<footnoteRef IDREF="t4f1"/>
                                 </td>
                                 <td styleCode="Rrule">45.5%</td>
                                 <td styleCode="Rrule">20.1%</td>
                                 <td styleCode="Rrule">39.0%</td>
                                 <td styleCode="Rrule">7.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Difference from Vehicle (95% CI)<footnoteRef IDREF="t4f2"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">24.8% (15.0%, 34.6%)</td>
                                 <td styleCode="Rrule" colspan="2">32.4% (23.3%, 41.6%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>SI-NRS success and WI-NRS success were defined as a reduction of at least 4 points from baseline with a baseline score of at least 4. In Trial ARRECTOR, among subjects with a baseline SI-NRS score of at least 4 (75% of subjects), a higher percentage of subjects achieved SI-NRS success at Week 8 in the group who received ZORYVE foam, 0.3%, compared to the group who received vehicle foam (65.3% vs. 30.3% for a treatment difference of 35.4% and 95% CI of (23.9, 47.0)). In Trial ARRECTOR, among subjects with a baseline WI-NRS score of at least 4 (72% of subjects), a higher percentage of subjects achieved WI-NRS success at Week 8 in the group who received ZORYVE foam, 0.3%, compared to the group who received vehicle foam (63.1% vs. 30.1% for a treatment difference of 32.8% and 95% CI of (20.3, 45.2)).</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="3a835322-a3ec-4788-8990-c7961abbf6b5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250527"/>
               <component>
                  <section>
                     <id root="33e72faf-8e95-4502-ab29-2ec604224be1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>ZORYVE (roflumilast) topical foam, 0.3%, is a white to off-white foam. It is supplied in a 60-gram pressurized aluminum can (NDC 80610-430-60).</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="013e58c9-ede4-4cba-bb3c-230496bd0cdb"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].</paragraph>
                        <paragraph>Do not freeze.</paragraph>
                        <paragraph>Store upright.</paragraph>
                        <paragraph>Flammable. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 49°C (120°F) <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="6db4b994-5a2e-4bfa-9da1-7e9955d32862"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <section>
                     <id root="1e1d0d5b-d104-4992-ab99-56cae88eff9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <paragraph>Advise patients or caregivers that ZORYVE foam, 0.3%, is for topical use only and is not for ophthalmic, oral, or intravaginal use <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Instruct patients or caregivers to shake the can of ZORYVE foam, 0.3%, prior to each use <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Instruct patients or caregivers to wash hands after applying ZORYVE foam, 0.3% <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b660ae95-51ca-4801-8f60-2043ca45ec45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Flammability</content>
                        </paragraph>
                        <paragraph>Because the propellants in ZORYVE foam, 0.3%, are flammable, instruct the patient to avoid fire, flame, and smoking during and immediately following application <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="122cc06a-dd85-46b9-8950-9906b9efa997"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise patients to use ZORYVE foam, 0.3%, on the smallest area of skin and for the shortest duration possible while breastfeeding. Instruct patients who are breastfeeding not to apply ZORYVE foam, 0.3%, directly to the nipple or areola to avoid direct infant exposure. Instruct patients to avoid inadvertent contact of treated areas with infant skin <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250527"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ddb9e705-cb82-4194-9425-893be7ab7de9"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Marketed by:</content>
                     <br/>Arcutis Biotherapeutics, Inc.<br/>Westlake Village, CA 91361</paragraph>
                  <paragraph>For more information on ZORYVE foam, call 1-805-418-5006 or visit http://www.zoryve.com.</paragraph>
                  <paragraph>© 2025 Arcutis Biotherapeutics, Inc. All rights reserved.</paragraph>
                  <paragraph>v2</paragraph>
               </text>
               <effectiveTime value="20250527"/>
            </section>
         </component>
         <component>
            <section ID="PPI">
               <id root="6dfc9822-35a5-40af-95c2-e0408c8dfce3"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="80%" align="left" valign="top"/>
                     <col width="20%" align="right" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" align="center" colspan="2">Patient Information<br/>ZORYVE<sup>®</sup> (zor-EEV)<br/>(roflumilast) topical foam, 0.3%</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="1">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" colspan="1">Revised: 5/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Important information: ZORYVE foam is for use on the skin (topical use) only.</content> Do not use ZORYVE foam in or on your eyes, mouth, or vagina.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What is ZORYVE foam?</content>
                              <br/>ZORYVE foam is a prescription medicine used on the skin (topical) to treat: 									<list listType="unordered" styleCode="Disc">
                                 <item>seborrheic dermatitis in adults and children 9 years of age and older.<br/>It is not known if ZORYVE foam is safe and effective in children with seborrheic dermatitis under 9 years of age.</item>
                                 <item>plaque psoriasis of the scalp and body in adults and children 12 years of age and older.<br/>It is not known if ZORYVE foam is safe and effective in children with plaque psoriasis of the scalp and body under 12 years of age.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Do not use ZORYVE foam if</content> you have certain liver problems.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Before using ZORYVE foam, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver problems.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if ZORYVE foam will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if ZORYVE foam passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ZORYVE foam.<br/>Breastfeeding women using ZORYVE foam should use it on the smallest area of the skin and for the shortest time needed. Do not apply ZORYVE foam directly to the nipple or areola to avoid contact with your baby. Avoid direct skin contact of treated areas with your baby if ZORYVE foam is applied to your chest.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">How should I use ZORYVE foam?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use ZORYVE foam exactly as your healthcare provider tells you to use it. See the "<linkHtml href="#IFU">Instructions for Use</linkHtml>" provided with this leaflet for directions about how to apply ZORYVE foam.</item>
                                 <item>Shake the can of ZORYVE foam before each use.</item>
                                 <item>Apply a thin layer of ZORYVE foam 1 time a day to the affected areas of your body and scalp when they are not wet. Rub the foam in completely.</item>
                                 <item>Wash your hands after applying ZORYVE foam. If someone else applies ZORYVE foam for you, they should wash their hands after applying it.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What should I avoid while using ZORYVE foam?<br/>ZORYVE foam is flammable.</content> Avoid fire, flame, and smoking during and right after you apply ZORYVE foam.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What are the possible side effects of ZORYVE foam?<br/>The most common side effects of ZORYVE foam in people treated for seborrheic dermatitis include:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>common cold</item>
                                 <item>nausea</item>
                                 <item>headache</item>
                              </list>
                              <content styleCode="bold">The most common side effects of ZORYVE foam in people treated for plaque psoriasis include:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>headache</item>
                                 <item>diarrhea</item>
                                 <item>nausea</item>
                                 <item>common cold</item>
                              </list>These are not all of the possible side effects of ZORYVE foam.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br/>You may also report side effects to Arcutis Biotherapeutics, Inc. by calling 1-844-692-6729.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">How should I store ZORYVE foam?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store ZORYVE foam at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>ZORYVE foam is flammable. Keep away from heat and flame.</item>
                                 <item>The contents in ZORYVE foam are under pressure. <content styleCode="bold">Do not</content> puncture or burn the can. <content styleCode="bold">Do not</content> expose the can to heat or store at temperatures above 120°F (49°C).</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze.</item>
                                 <item>Store the can upright.</item>
                              </list>
                              <content styleCode="bold">Keep ZORYVE foam and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">General Information about the safe and effective use of ZORYVE foam.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZORYVE foam for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZORYVE foam that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What are the ingredients in ZORYVE foam?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> roflumilast<br/>
                              <content styleCode="bold">Inactive ingredients:</content> ceteareth-10 phosphate, cetearyl phosphate, cetostearyl alcohol, diethylene glycol monoethyl ether, hexylene glycol, isopropyl palmitate, methylparaben, propylparaben, purified water, sodium hydroxide, and white petrolatum. Hydrochloric acid may have been added to adjust pH.<br/>
                              <content styleCode="bold">Propellants:</content> butane, isobutane, and propane.<br/>
                              <content styleCode="bold">Marketed by:</content>
                              <br/>Arcutis Biotherapeutics, Inc.<br/>Westlake Village, CA 91361<br/>For more information on ZORYVE topical foam, call 1-844-692-6729 or visit http://www.zoryve.com.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>v2</paragraph>
               </text>
               <effectiveTime value="20250527"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="f9722498-98e7-4162-ba7c-c5866cb9370f"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE<br/>ZORYVE<sup>®</sup> (zor-EEV)<br/>(roflumilast) topical foam, 0.3%</title>
               <text>
                  <paragraph>This Instructions for Use contains information on how to apply ZORYVE foam.</paragraph>
                  <paragraph>Read this Instructions for Use before you start using ZORYVE foam and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. Use ZORYVE foam exactly as your healthcare provider tells you.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before applying ZORYVE foam:</content>
                  </paragraph>
                  <list>
                     <item>
                        <content styleCode="bold">ZORYVE foam is for use on skin only (topical use).</content> ZORYVE foam is not for use in your eyes, mouth, or vagina.</item>
                     <item>
                        <content styleCode="bold">ZORYVE foam is flammable.</content> Avoid fire, flame, and smoking during and right after you apply ZORYVE foam.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before applying ZORYVE foam for the first time:</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20%" align="left" valign="bottom"/>
                     <col width="80%" align="left" valign="bottom"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                           <td>Gently pull back on the nozzle to break the plastic piece at the base.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Applying ZORYVE foam:</content>
                  </paragraph>
                  <paragraph>Apply a thin layer of ZORYVE foam <content styleCode="bold">1 time a day</content> to the affected areas of your body and scalp when they are not wet.</paragraph>
                  <table width="100%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 1: Shake.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Shake the can well before each use.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM3"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 2: Dispense.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Turn the can upside down and press the nozzle.</item>
                                 <item>Dispense a small amount into your hand.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Step 3: Apply.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use enough ZORYVE foam to cover all affected areas with a thin layer. Rub the foam in completely.</item>
                                 <item>If you are treating your scalp, part the hair so that ZORYVE foam can be applied directly to the affected area on the skin.</item>
                                 <item>Wash your hands after applying the medicine. If someone else applies ZORYVE foam for you, they should wash their hands after applying it.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM5"/>
                              <br/>
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Storing ZORYVE foam</content>
                  </paragraph>
                  <list>
                     <item>Store ZORYVE foam at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>ZORYVE foam is flammable. Keep away from heat and flame.</item>
                     <item>The contents in ZORYVE foam are under pressure. <content styleCode="bold">Do not</content> puncture or burn the can. <content styleCode="bold">Do not</content> expose the can to heat or store at temperatures above 120°F (49°C).</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze.</item>
                     <item>Store the can upright.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep ZORYVE foam and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Marketed by:</content>
                     <br/>Arcutis Biotherapeutics, Inc.<br/>Westlake Village, CA 91361</paragraph>
                  <paragraph>For more information on ZORYVE foam, call 1-844-692-6729 or visit http://www.zoryve.com.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 5/2025</paragraph>
                  <paragraph>v2</paragraph>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b7240d17-4980-48d8-91c3-fdf4861bb547"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 60 g Can Carton</title>
               <text>
                  <paragraph>NDC 80610-430-60</paragraph>
                  <paragraph>ZORYVE<sup>®</sup>
                     <br/> (roflumilast)<br/> topical foam, 0.3%</paragraph>
                  <paragraph>Rx Only<br/> 60 grams</paragraph>
                  <paragraph>For Topical Use Only</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250527"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 60 g Can Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="zoryve-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>